NEW YORK, May 12, 2017 /PRNewswire/ --
Stock-Callers.com is currently reviewing the most recent performances of Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Dynavax Technologies Corp. (NASDAQ: DVAX), Intrexon Corp. (NYSE: XON), and Heat Biologics Inc. (NASDAQ: HTBX). Biotech firms differ from conventional drug makers, in that they utilize natural ingredients as opposed to synthetic ones. Learn more about these stocks by downloading their comprehensive and free reports at:
On Thursday, shares in New York-based Progenics Pharmaceuticals Inc. rose 1.25%, ending the day at $7.30. The stock recorded a trading volume of 785,663 shares. The Company's shares are trading below their 200-day moving average by 8.85%. Moreover, shares of Progenics Pharma, which develops medicines and other technologies to target and treat cancer in the US and internationally, have a Relative Strength Index (RSI) of 37.98.
On May 04th, 2017, Progenics Pharma announced financial results for Q1 2017. Revenue for Q1 2017 totaled $2.3 million, down from $2.5 million in Q1 2016. Net loss attributable to the Company for the quarter was $16.4 million, compared to a net loss of $12.7 million in the corresponding 2016 period. Additionally, R&D expenses increased by $0.9 million, and general and administrative expenses decreased by $0.1 million during the quarter. PGNX complete research report is just a click away and free at:
Shares in Berkeley, California headquartered Dynavax Technologies Corp. ended the day 0.89% lower at $5.55 with a total trading volume of 607,211 shares. In the last month and the previous three months, the stock has gained 6.73% and 38.75%, respectively. Additionally, the Company's shares have advanced 40.51% on an YTD basis. The stock is trading below its 50-day moving average by 3.23%. Furthermore, shares of Dynavax Technologies, which focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation, have an RSI of 49.19.
On May 08th, 2017, Dynavax Technologies reported financial results for Q1 2017. Cash, cash equivalents, and marketable securities were $85.4 million at March 31st, 2017; net loss was $25.3 million, or $0.60 per share; R&D expenses were $16.3 million; and general and administrative expenses were $6.5 million.
On May 09th, 2017, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with an increase of the target price from $6 a share to $7 a share. The complimentary report on DVAX can be downloaded at:
At the close of trading on Thursday, shares in Germantown, Maryland-based Intrexon Corp. finished 20.76% higher at $23.62. A total volume of 5.32 million shares was traded, which was above their three months average volume of 1.07 million shares. The stock has advanced 20.02% in the last one month and 9.10% over the previous three months. The Company's shares are trading above their 50-day moving average by 14.65%. Additionally, shares of Intrexon, which operates in the synthetic biology field in the US, have an RSI of 69.39.
On May 10th, 2017, Intrexon and Darling Ingredients Inc. announced that their joint venture, EnviroFlight, LLC, plans to significantly expand production of advanced ingredients for sustainable feed and nutrition derived from black soldier fly (BSF) larvae through the largest, commercial-scale BSF larvae production facility in the US. Initial production capacity is expected in Q1 2018, and will be targeted toward supplying livestock, aquaculture, and pet food markets. Sign up for your complimentary research report on XON at:
Durham, North Carolina-based Heat Biologics Inc.'s shares recorded a trading volume of 153,023 shares at the end of yesterday's session. The stock closed the day 3.55% higher at $0.73. The Company's shares are trading below their 50-day moving average by 12.21%. Additionally, shares of Heat Biologics, which focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the US, have an RSI of 38.38.
On May 01st, 2017, Heat Biologics announced that the Company has completed the acquisition of an 80% controlling interest in Pelican Therapeutics, Inc., a privately held immuno-oncology company focused on developing agonists to TNFRSF25, a differentiated and potentially best-in-class T cell costimulatory receptor. Heat also announced its appointment of industry veteran and Pelican board member Rahul Jasuja, Ph.D. as the new CEO of the Pelican subsidiary. Get free access to your research report on HTBX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA